Current Value
$19.851 Year Return
Current Value
$19.851 Year Return
Yahoo
FDA Breakthrough Therapy Designation received for tividenofusp alfa for Hunter syndrome (MPS II); on track to submit biologics license application (BLA) in early 2025Preparing for commercial launch of tividenofusp alfa for Hunter syndrome in late 2025 or early 2026Enable accelerated approval pathway for DNL126 for Sanfilippo syndrome Type A (MPS IIIA)Expand and advance portfolio of multiple TransportVehicleTM (TV) enabled programs for delivery of enzyme, oligonucleotide, and antibody therapeutic
SeekingAlpha
NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's potential impact on NGENF's stock value.
Yahoo
Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.
SeekingAlpha
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click for my DNLI stock update.
Yahoo
Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathwaySOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment of individuals with Hunter syndrome (MPS II). This designation is in addition to Fas
Yahoo
BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares after the company announced topline data from the Phase 2/3 HEALEY trial which was testing an agonist of eIF2B for amyotrophic lateral sclerosis. The DNL343 failure is sobering as the program was backed by convincing pre-clinical data showing reduced aggregation of key drivers of ALS pathology such as TDP-43, the analyst tells investors in a research note
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NERV | -22.56% | $14.86M | -69.42% | 0.00% |
TCTM | -13.97% | $3.49M | -65.16% | 0.00% |
CBOE | -13.94% | $20.24B | +5.28% | 1.22% |
CCEC | -8.93% | $1.05B | +11.04% | 3.17% |
CME | -8.36% | $83.51B | +16.68% | 4.47% |
TEM | -6.38% | $5.01B | 0.00% | 0.00% |
PRPO | -6.31% | $8.98M | +14.99% | 0.00% |
BTCT | -6.23% | $20.96M | -19.65% | 0.00% |
PSQH | -5.84% | $156.33M | -32.47% | 0.00% |
HUSA | -5.53% | $21.33M | 0.00% | 0.00% |
STG | -4.88% | $28.93M | -36.25% | 0.00% |
K | -4.61% | $28.07B | +50.41% | 2.78% |
PRT | -4.46% | $50.49M | -10.61% | 10.10% |
SRRK | -3.63% | $3.89B | +161.03% | 0.00% |
FATBB | -3.50% | $80.60M | -15.34% | 11.94% |
TRVG | -3.23% | $59.69M | +6.83% | 0.00% |
MCK | -3.18% | $75.37B | +21.54% | 0.45% |
MNOV | -2.89% | $93.68M | +25.66% | 0.00% |
PRGO | -2.45% | $3.21B | -28.76% | 4.61% |
FUBO | -2.27% | $1.29B | +43.23% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CPSH | -0.05% | $24.98M | -24.89% | 0.00% |
HIHO | 0.10% | $8.50M | -5.62% | 6.22% |
GLP | 0.14% | $1.67B | +11.57% | 5.73% |
WLKP | -0.19% | $834.10M | +3.05% | 7.91% |
VIST | 0.25% | $5.59B | +92.50% | 0.00% |
STGW | 0.27% | $702.28M | -3.93% | 0.00% |
SHEL | -0.27% | $205.50B | +6.72% | 4.17% |
PG | 0.32% | $376.19B | +6.64% | 2.48% |
PAC | 0.33% | $8.31B | +25.81% | 0.00% |
DV | 0.43% | $3.25B | -47.32% | 0.00% |
VHC | -0.50% | $28.64M | +23.67% | 0.00% |
FLNG | 0.55% | $1.40B | -12.41% | 11.49% |
LPL | 0.55% | $3.25B | -31.58% | 0.00% |
HES | -0.66% | $45.19B | +6.07% | 1.28% |
FRO | 0.67% | $4.11B | -17.15% | 10.39% |
INSP | -0.80% | $5.09B | -8.66% | 0.00% |
COKE | 0.81% | $11.32B | +44.73% | 0.31% |
APT | -0.83% | $61.92M | +8.69% | 0.00% |
TXO | -0.86% | $728.26M | -5.77% | 13.25% |
POST | -0.88% | $6.25B | +15.69% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BEAM | 61.01% | $1.93B | -7.17% | 0.00% |
DORM | 56.28% | $3.84B | +55.21% | 0.00% |
HSII | 55.98% | $928.22M | +67.70% | 1.29% |
VKTX | 55.77% | $3.78B | +59.60% | 0.00% |
LGND | 55.41% | $2.05B | +52.74% | 0.00% |
CDXS | 51.73% | $368.64M | +67.16% | 0.00% |
NTLA | 51.57% | $991.50M | -63.62% | 0.00% |
AHCO | 51.04% | $1.40B | +55.94% | 0.00% |
RCKT | 49.55% | $1.11B | -63.43% | 0.00% |
PRTA | 48.55% | $681.76M | -61.75% | 0.00% |
RGNX | 48.48% | $349.29M | -53.83% | 0.00% |
CRSP | 48.22% | $3.27B | -39.52% | 0.00% |
ACLX | 47.29% | $3.50B | +18.08% | 0.00% |
ALLO | 47.17% | $402.57M | -38.66% | 0.00% |
PLRX | 46.02% | $683.99M | -36.17% | 0.00% |
LCII | 45.71% | $2.59B | -15.07% | 4.08% |
ALEC | 45.61% | $160.12M | -78.60% | 0.00% |
NCLH | 44.64% | $11.43B | +50.72% | 0.00% |
GMRE | 44.13% | $522.40M | -25.24% | 10.40% |
PUBM | 43.98% | $668.73M | -1.48% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 68.92% | $6.18B | 0.35% |
GNOM | 62.96% | $68.90M | 0.5% |
IBB | 60.52% | $6.41B | 0.45% |
PTH | 60.30% | $117.64M | 0.6% |
ARKG | 60.00% | $1.09B | 0.75% |
XPH | 56.36% | $155.81M | 0.35% |
PBE | 55.61% | $255.43M | 0.58% |
IWC | 55.55% | $927.11M | 0.6% |
IWO | 55.02% | $12.47B | 0.24% |
RSPA | 54.92% | $268.92M | 0% |
IWM | 54.32% | $70.21B | 0.19% |
VTWO | 54.21% | $12.12B | 0.1% |
FBT | 53.19% | $1.17B | 0.56% |
ISCG | 52.94% | $633.06M | 0.06% |
ESML | 51.92% | $1.87B | 0.17% |
SMMD | 51.48% | $1.35B | 0.15% |
IWN | 51.48% | $11.95B | 0.24% |
NUSC | 51.17% | $1.21B | 0.31% |
RZV | 51.12% | $236.34M | 0.35% |
IJS | 50.99% | $7.39B | 0.18% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -25.68% | $195.31M | 0.85% |
USDU | -16.32% | $390.63M | 0.5% |
TAIL | -14.03% | $65.48M | 0.59% |
UUP | -12.50% | $640.67M | 0.77% |
CTA | -8.46% | $536.34M | 0.76% |
DBE | -7.22% | $50.63M | 0.77% |
DBO | -5.72% | $228.06M | 0.77% |
COMT | -4.01% | $717.70M | 0.48% |
USCI | -3.75% | $200.39M | 1.07% |
CORN | -3.12% | $65.39M | 0.2% |
PDBC | -3.02% | $4.29B | 0.59% |
GSG | -2.39% | $1.07B | 0.75% |
BILZ | -2.18% | $616.87M | 0.14% |
WEAT | -2.02% | $121.69M | 0.28% |
UNG | -1.83% | $820.81M | 1.06% |
TPMN | -1.62% | $41.70M | 0.65% |
FLTR | -1.57% | $1.97B | 0.14% |
IBD | -1.49% | $332.90M | 0.44% |
DBA | -1.11% | $812.87M | 0.93% |
EQLS | -1.04% | $8.93M | 1% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
SOYB | 0.25% | $26.14M | 0.22% |
KCCA | 0.42% | $116.67M | 0.87% |
GBIL | -0.59% | $5.82B | 0.12% |
DBC | -0.90% | $1.35B | 0.87% |
EQLS | -1.04% | $8.93M | 1% |
DBA | -1.11% | $812.87M | 0.93% |
IBD | -1.49% | $332.90M | 0.44% |
TBLL | 1.54% | $2.00B | 0.08% |
FLTR | -1.57% | $1.97B | 0.14% |
TPMN | -1.62% | $41.70M | 0.65% |
UNG | -1.83% | $820.81M | 1.06% |
WEAT | -2.02% | $121.69M | 0.28% |
BILZ | -2.18% | $616.87M | 0.14% |
GSG | -2.39% | $1.07B | 0.75% |
KMLM | 2.44% | $333.89M | 0.9% |
VRIG | 2.61% | $1.20B | 0.3% |
FTGC | 2.62% | $2.33B | 1.02% |
BCI | 2.84% | $1.36B | 0.26% |
PDBC | -3.02% | $4.29B | 0.59% |
CORN | -3.12% | $65.39M | 0.2% |